Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
The European Chamber of Commerce in Korea (ECCK) is the pre-eminent association of European companies conducting business in or related to Korea. Representing the common voice of the European business community in Korea, the ECCK aims to function as the platform for information exchange, effective communication channel to the Korean authorities and convenor of networking opportunities for European businesses. The ECCK is a non-profit and non-political organisation.
The ECCK was officially founded on 3 December 2012, upon the approval of the Ministry of Knowledge Economy (Ministry of Trade, Industry and Energy as of 2013). With its clear legal status defined under Korea’s Chamber of Commerce and Industry Act of 2008, the ECCK has focused on transparency and co-operation as its fundamental values.
The ECCK maintains its open door policy of actively listening to members’ opinions and suggestions in developing its programmes and activities. The ECCK seeks for collaboration with national chambers of commerce and European business associations to identify issues of common concern and effectively represent the interests of the European business community.
The ECCK is a strong believer in mutual prosperity. The ECCK hopes to contribute to fostering an optimal business climate for both European and local Korean companies. Moreover, as a good corporate citizen, the ECCK is determined to develop and carry out activities for the benefit of the Korean society.
The organisation is governed by the Board of Directors, entrusted with members’ mandate. The Advisory Board, comprised of national chambers and embassies, provides guidance and advice in regard to direction and activities. The Secretariat manages daily operation and activities of the Chamber.
Address
5F, Seoul Square, 416 Hangang-daero, Jung-gu,
Seoul 100-714, Korea
서울특별시중구한강대로 416 서울스퀘어 5층
(우 100-714)
Tel +82 2 6261 2700
Fax +82 2 6261 2730
E-mail ecck@ecck.eu
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
See our Cookie Privacy Policy Here